NUVA

Globus Medical completes merger with NuVasive

PremiumThe Fly

1y ago

Goosehead Insurance to replace NuVasive in S&P 600 at open on 9/1

PremiumThe Fly

1y ago

Goosehead Insurance to replace NuVasive in S&P 600 at open on 9/1

GSHD

PremiumThe Fly

1y ago

NuVasive price target raised to $58 from $56 at Barclays

GSHD

PremiumThe Fly

1y ago

PremiumThe FlyNuVasive still expects 2023 net sales growth 6%-8%, revenue consensus $1.29B

1y ago

The Fly

NuVasive reports Q2 non-GAAP EPS 56c, consensus 55c

1y ago

The Fly

NuVasive price target raised to $51 from $48 at Truist

1y ago

NUVA Earnings Report this Week: Is It a Buy, Ahead of Earnings?

PremiumPre-Earnings

2y ago

Globus Medical shareholders approve share issuance for NuVasive merger

PremiumThe Fly

2y ago

NuVasive shareholders approve merger agreement with Globus Medical

PremiumThe Fly

2y ago

NuVasive says Glass Lewis recommends shareholders vote for Globus merger

PremiumThe Fly

2y ago

PremiumThe FlyTD Cowen medical devices analyst to hold analyst/industry conference call

2y ago

The Fly

TD Cowen medical devices analyst to hold analyst/industry conference call

2y ago

The Fly

NuVasive says ISS recommends vote in favor of Globus deal

2y ago

TD Cowen medical devices analyst to hold analyst/industry conference call

PremiumThe Fly

2y ago

TD Cowen medical devices analyst to hold analyst/industry conference call

PremiumThe Fly

2y ago

TD Cowen medical devices analyst to hold analyst/industry conference call

PremiumThe Fly

2y ago

NuVasive, Globus Medical continue to expect transaction to close mid-2023

PremiumThe Fly

2y ago

PremiumThe FlyCanaccord upgrades Globus Medical with merger uncertainty priced in

2y ago

The Fly

NuVasive gets FDA 510(k) clearance for Precice limb lengthening solution

2y ago

The Fly

NuVasive reports Q4 non-GAAP EPS 43c, consensus 51c

2y ago